Alto Neuroscience
ANRO
83 hedge funds and large institutions have $45M invested in Alto Neuroscience in 2025 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 18 increasing their positions, 27 reducing their positions, and 12 closing their positions.
58% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 12
8% more funds holding
Funds holding: 77 → 83 (+6)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6.53% less ownership
Funds ownership: 83.54% → 77.01% (-6.5%)
21% less call options, than puts
Call options by funds: $50K | Put options by funds: $63K
33% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 27
53% less capital invested
Capital invested by funds: $95.3M → $45M (-$50.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$3.4M |
| 2 |
AIC
AWM Investment Company
New York
|
+$766K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$386K |
| 4 |
IHAM
Integral Health Asset Management
New York
|
+$358K |
| 5 |
SCM
SCS Capital Management
Boston,
Massachusetts
|
+$239K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.83M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$1.7M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.62M |
| 4 |
CF
Cantor Fitzgerald
New York
|
-$1.2M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$938K |
ANRO Hedge Fund Activity: Q1 2025 in Review
83 of the 7,473 institutional investors tracked by Wall St. Rank reported a position in Alto Neuroscience (ANRO) for Q1 2025, worth a combined $45M — down 53% from $95.3M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ANRO positions and 12 closed out — a net gain of 7 holders — while 18 added to existing stakes and 27 trimmed.
The largest buyer was Armistice Capital, adding an estimated $3.4M. The largest seller was T. Rowe Price Associates, cutting an estimated $2.83M.
- 83 institutional investors held Alto Neuroscience (ANRO) as of Q1 2025, up from 77 in Q4 2024.
- Funds reported $45M of Alto Neuroscience stock for Q1 2025, down 53% quarter-over-quarter.
- 19 funds opened new Alto Neuroscience positions in Q1 2025 and 12 closed out, a net change of +7 holders.
- The largest Alto Neuroscience buyer in Q1 2025 was Armistice Capital, an estimated $3.4M added.
- The largest Alto Neuroscience seller in Q1 2025 was T. Rowe Price Associates, an estimated $2.83M sold.
Based on aggregated 13F filings for Q1 2025.